IDBS Blog | 18th September 2017
Our Thoughts from Brussels: The IDBS Interactive Workshop 2017
Our popular Community Forums have been running for several years now, so we decided to mix things up a bit for our latest event in Brussels, at Solvay’s HQ!
We transformed the event into a VIP interactive workshop with a select group of attendees (and with lunch on the side, for good measure). Solvay kicked off the day with an excellent discussion around their implementation of The E-WorkBook Cloud, explaining how they saw operational benefits in their labs almost immediately.
Throughout the day, attendees openly shared their own R&D challenges with our experts, and learnt how our ‘powerful, flexible and user-friendly’ (Solvay’s words, not ours!) technology could fit into their organizations, while also discussing broader topics like cloud, SaaS, and where technology is heading.
It was a busy, productive day, and well worth it – we’re already looking forward to our next interactive workshop in 2018. Watch this space…
If you would like to attend one of our future interactive workshops – in either Europe or the US – let us know at marketing-info@idbs.com, and we’ll make sure you’re the first to know about our upcoming events.
More news
Ensuring product, process and patient data integrity and traceability throughout the BioPharmaceutical lifecycle in the era of personalized medicine
The BioPharma industry is facing a multitude of challenging external trends, from the growth in personalized medicine to supply chain disruptions and more.
European Biomanufacturing Summit 2023
Come and join us at booth 130 in Amsterdam, to learn how an innovative tech transfer approach can revolutionize drug manufacturing in the pharmaceutical industry.
IDBS events roundup: Q1 highlights and Q2 events
IDBS associates had the opportunity to attend some events in Q1 and attendees were eager to see, hear and learn more about what’s happening in the industry.
How to improve time-to-value using GxP computer systems
Explore the benefits of GxP computer systems to improve time-to-value so that companies can speed up the development and manufacture of life-saving drugs.